Westbourne Investments Inc. Cuts Position in Pfizer Inc. $PFE

Key Points

• Westbourne Investments Inc. reduced its position in Pfizer Inc. by 14.3%, currently holding 81,595 shares after the sale of 13,570 shares in Q2.
• Pfizer reported $0.78 EPS for the last quarter, exceeding analysts' expectations of $0.58, with a revenue of $14.65 billion.
• The company announced a quarterly dividend of $0.43 per share, representing an annualized dividend of $1.72 with a yield of 7.2%.

Westbourne Investments Inc. reduced its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 14.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 81,595 shares of the biopharmaceutical company's stock after selling 13,570 shares during the period. Westbourne Investments Inc.'s holdings in Pfizer were worth $1,978,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Gould Capital LLC boosted its holdings in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. purchased a new position in Pfizer in the first quarter worth approximately $27,000. North Capital Inc. purchased a new position in Pfizer in the first quarter worth approximately $28,000. Bayforest Capital Ltd purchased a new position in Pfizer in the first quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in Pfizer in the fourth quarter worth approximately $30,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Down 0.4%

PFE opened at $23.88 on Wednesday. The business's 50-day simple moving average is $24.73 and its 200-day simple moving average is $24.25. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The stock has a market capitalization of $135.77 billion, a P/E ratio of 12.70, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the previous year, the firm earned $0.60 earnings per share. The business's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were given a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. Pfizer's payout ratio is 91.49%.

Wall Street Analyst Weigh In

PFE has been the subject of several analyst reports. Morgan Stanley increased their price objective on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Berenberg Bank lowered their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Bank of America increased their price objective on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Jefferies Financial Group upped their price target on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. Finally, Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.